Norepinephrine:the next therapeutics frontier for Parkinson’s disease  

作　　者：Peter A LeWitt 

机构地区：[1]Department of Neurology,Henry Ford Hospital and Wayne State University School of Medicine,Detroit,Michigan USA

出　　处：《Translational Neurodegeneration》2012年第1期20-23,共4页转化神经变性病（英文）

摘　　要：Tissue concentrations of norepinephrine(NE)are markedly decreased in various regions of the Parkinson’s disease(PD)brain.As in the substantia nigra pars compacta,neuronal dropout and Lewy bodies are prominent changes affecting the locus coeruleus,which is the source of ascending NErgic projections.Despite the major roles of NE throughout the brain,there has been only minimal exploration of pharmacological intervention with NErgic neurotransmission.Cognitive operations,“freezing”of gait,tremor,dyskinesia,REM sleep regulation,and other aspects of brain function are tied into signaling by NE,and there is also evidence that it may have a role in the neurodegenerative process itself.This article reviews the reported pharmacological experience in PD therapeutics.

关 键 词：NOREPINEPHRINE Parkinson??s disease NEUROPHARMACOLOGY 

分 类 号：R74[医药卫生—神经病学与精神病学]